Radioembolization of hepatocarcinoma with 90Y glass microspheres: development of an individualized treatment planning strategy based on dosimetry and radiobiology

[1]  N. Lanconelli,et al.  Differences in 3D dose distributions due to calculation method of voxel S-values and the influence of image blurring in SPECT , 2015, Physics in medicine and biology.

[2]  S. Walrand,et al.  A Hepatic Dose-Toxicity Model Opening the Way Toward Individualized Radioembolization Planning , 2014, The Journal of Nuclear Medicine.

[3]  P. Flamen,et al.  Pretreatment Dosimetry in HCC Radioembolization with 90Y Glass Microspheres Cannot Be Invalidated with a Bare Visual Evaluation of 99mTc-MAA Uptake of Colorectal Metastases Treated with Resin Microspheres , 2014, The Journal of Nuclear Medicine.

[4]  F. Orsi,et al.  Radioembolization of Hepatic Lesions from a Radiobiology and Dosimetric Perspective , 2014, Front. Oncol..

[5]  A. Pasciak,et al.  A Comparison of Techniques for 90Y PET/CT Image-Based Dosimetry Following Radioembolization with Resin Microspheres , 2014, Front. Oncol..

[6]  P. Flamen,et al.  Corrigendum: Multimodality imaging can predict the metabolic response of unresectable colorectal liver metastases to radioembolization therapy with Yttrium-90 labeled resin microspheres (2008 Phys. Med. Biol. 53 6591–603) , 2014 .

[7]  V. Mazzaferro,et al.  The dosimetric importance of the number of 90Y microspheres in liver transarterial radioembolization (TARE) , 2014, European Journal of Nuclear Medicine and Molecular Imaging.

[8]  S. Walrand,et al.  The Low Hepatic Toxicity per Gray of 90Y Glass Microspheres Is Linked to Their Transport in the Arterial Tree Favoring a Nonuniform Trapping as Observed in Posttherapy PET Imaging , 2014, The Journal of Nuclear Medicine.

[9]  Bruno Sangro,et al.  Yttrium 90 radioembolization for the treatment of hepatocellular carcinoma: Biological lessons, current challenges, and clinical perspectives , 2013, Hepatology.

[10]  Michael Ljungberg,et al.  MIRD Pamphlet No. 24: Guidelines for Quantitative 131I SPECT in Dosimetry Applications , 2013, The Journal of Nuclear Medicine.

[11]  Marnix G E H Lam,et al.  99mTc-Macroaggregated Albumin Poorly Predicts the Intrahepatic Distribution of 90Y Resin Microspheres in Hepatic Radioembolization , 2013, The Journal of Nuclear Medicine.

[12]  D. Townsend,et al.  Post-radioembolization yttrium-90 PET/CT - part 2: dose-response and tumor predictive dosimetry for resin microspheres , 2013, EJNMMI Research.

[13]  I Syndikus,et al.  Alpha emitter radium-223 and survival in metastatic prostate cancer. , 2013, The New England journal of medicine.

[14]  Carlo Morosi,et al.  Yttrium‐90 radioembolization for intermediate‐advanced hepatocellular carcinoma: A phase 2 study , 2013, Hepatology.

[15]  K. Boudjema,et al.  Boosted selective internal radiation therapy with 90Y-loaded glass microspheres (B-SIRT) for hepatocellular carcinoma patients: a new personalized promising concept , 2013, European Journal of Nuclear Medicine and Molecular Imaging.

[16]  H. Amthauer,et al.  Predictive Value of Intratumoral 99mTc-Macroaggregated Albumin Uptake in Patients with Colorectal Liver Metastases Scheduled for Radioembolization with 90Y-Microspheres , 2013, The Journal of Nuclear Medicine.

[17]  V. Mazzaferro,et al.  A dosimetric treatment planning strategy in radioembolization of hepatocarcinoma with 90Y glass microspheres. , 2012, The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of....

[18]  Yuni K. Dewaraja,et al.  MIRD Pamphlet No. 23: Quantitative SPECT for Patient-Specific 3-Dimensional Dosimetry in Internal Radionuclide Therapy , 2012, The Journal of Nuclear Medicine.

[19]  S. Walrand,et al.  Hemoglobin level significantly impacts the tumor cell survival fraction in humans after internal radiotherapy , 2012, EJNMMI Research.

[20]  Y. Rolland,et al.  Dosimetry Based on 99mTc-Macroaggregated Albumin SPECT/CT Accurately Predicts Tumor Response and Survival in Hepatocellular Carcinoma Patients Treated with 90Y-Loaded Glass Microspheres: Preliminary Results , 2012, The Journal of Nuclear Medicine.

[21]  Wenzheng Feng,et al.  Recommendations of the American Association of Physicists in Medicine on dosimetry, imaging, and quality assurance procedures for 90 Y microsphere brachytherapy in the treatment of hepatic malignancies. , 2011, Medical physics.

[22]  William Y. Song,et al.  A comparison of dose-response characteristics of four NTCP models using outcomes of radiation-induced optic neuropathy and retinopathy , 2011, Radiation oncology.

[23]  V. Mazzaferro,et al.  Need, feasibility and convenience of dosimetric treatment planning in liver selective internal radiation therapy with (90)Y microspheres: the experience of the National Tumor Institute of Milan. , 2011, The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of....

[24]  Lidia Strigari,et al.  Efficacy and Toxicity Related to Treatment of Hepatocellular Carcinoma with 90Y-SIR Spheres: Radiobiologic Considerations , 2010, The Journal of Nuclear Medicine.

[25]  M. Luster,et al.  EANM procedure guidelines for therapy of benign thyroid disease , 2010, European Journal of Nuclear Medicine and Molecular Imaging.

[26]  Samer Ezziddin,et al.  Radioembolization of liver tumors with yttrium-90 microspheres. , 2010, Seminars in nuclear medicine.

[27]  P. Flamen,et al.  Multimodality imaging can predict the metabolic response of unresectable colorectal liver metastases to radioembolization therapy with Yttrium-90 labeled resin microspheres , 2008, Physics in medicine and biology.

[28]  F. Orsi,et al.  Radioembolisation with 90Y-microspheres: dosimetric and radiobiological investigation for multi-cycle treatment , 2008, European Journal of Nuclear Medicine and Molecular Imaging.

[29]  B. Erickson,et al.  Estimate of radiobiologic parameters from clinical data for biologically based treatment planning for liver irradiation. , 2008, International journal of radiation oncology, biology, physics.

[30]  E. Lin,et al.  Conformal Radiotherapy of the Dominant Liver Metastasis: A Viable Strategy For Treatment of Unresectable Chemotherapy Refractory Colorectal Cancer Liver Metastases , 2006, American journal of clinical oncology.

[31]  R. T. Ten Haken,et al.  Partial volume tolerance of the liver to radiation. , 2005, Seminars in radiation oncology.

[32]  R K Ten Haken,et al.  Partial irradiation of the liver. , 2001, Seminars in radiation oncology.

[33]  Maxon Hr.  Quantitative radioiodine therapy in the treatment of differentiated thyroid cancer. , 1999 .

[34]  J. O’Donoghue,et al.  Implications of nonuniform tumor doses for radioimmunotherapy. , 1999, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[35]  A. Agresti,et al.  Approximate is Better than “Exact” for Interval Estimation of Binomial Proportions , 1998 .

[36]  R G Dale,et al.  Dose-rate effects in targeted radiotherapy. , 1996, Physics in medicine and biology.

[37]  A. Li,et al.  Partition model for estimating radiation doses from yttrium-90 microspheres in treating hepatic tumours , 1996, European Journal of Nuclear Medicine.

[38]  A. Li,et al.  Treatment of inoperable hepatocellular carcinoma with intrahepatic arterial yttrium-90 microspheres: a phase I and II study. , 1994, British Journal of Cancer.

[39]  B. Fertil,et al.  Intrinsic radiosensitivity of human cell lines is correlated with radioresponsiveness of human tumors: analysis of 101 published survival curves. , 1985, International journal of radiation oncology, biology, physics.

[40]  V S Hertzberg,et al.  Relation between effective radiation dose and outcome of radioiodine therapy for thyroid cancer. , 1983, The New England journal of medicine.

[41]  J. Hanley,et al.  A method of comparing the areas under receiver operating characteristic curves derived from the same cases. , 1983, Radiology.

[42]  G. Sgouros,et al.  Patient-Specific Dosimetry, Radiobiology, and the Previously-Treated Patient , 2012 .

[43]  Wenzheng Feng,et al.  Recommendations of the American Association of Physicists in Medicine on dosimetry, imaging, and quality assurance procedures for 90Y microsphere brachytherapy in the treatment of hepatic malignancies. , 2011, Medical physics.

[44]  M. Lassmann,et al.  EANM Dosimetry Committee guidance document: good practice of clinical dosimetry reporting , 2010, European Journal of Nuclear Medicine and Molecular Imaging.

[45]  Raffaella Barone,et al.  Patient-specific dosimetry in predicting renal toxicity with (90)Y-DOTATOC: relevance of kidney volume and dose rate in finding a dose-effect relationship. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[46]  P W Hoban,et al.  Treatment plan comparison using equivalent uniform biologically effective dose (EUBED). , 2000, Physics in medicine and biology.

[47]  H. Maxon.  Quantitative radioiodine therapy in the treatment of differentiated thyroid cancer. , 1999, The quarterly journal of nuclear medicine : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology.

[48]  G J Kutcher,et al.  Analysis of clinical complication data for radiation hepatitis using a parallel architecture model. , 1995, International journal of radiation oncology, biology, physics.

[49]  J. Lyman.  Complication probability as assessed from dose-volume histograms. , 1985, Radiation research. Supplement.